Secret £64bn UK-US Pharma Deal Could Cause 330,000 Excess Deaths, Experts Warn
A secretive £64 billion pharmaceutical deal between the UK and US governments, published on 13 April 2026, has ignited a major public health controversy, with leading health economists warning it could lead to hundreds of thousands of excess deaths in the UK by 2033 — while the government insists the figures are overstated.
The deal, reportedly struck after the Trump administration threatened crippling tariffs on pharmaceuticals, commits the NHS to spending significantly more on new medicines and alters the assessment process used by the National Institute for Health and Care Excellence (NICE). Critics say it could divert vast sums from other essential health services.
Background
The UK-US pharmaceutical deal was negotiated as part of broader trade discussions between London and Washington. Details were published on 13 April 2026 following an investigation by the Bureau of Investigative Journalism. The deal changes how NICE evaluates the cost-effectiveness of new drugs, potentially allowing pharmaceutical companies to charge higher prices for medicines supplied to the NHS.
Key Developments
Health economist Professor Karl Claxton estimated the deal could cost the UK up to £64 billion by 2036 and result in an additional 330,000 deaths — as money diverted to expensive new drugs would otherwise have funded treatments that save more lives per pound spent. The government disputed these figures, while the Association of the British Pharmaceutical Industry (ABPI) dismissed the research as "fundamentally flawed."
The lack of parliamentary scrutiny of the deal has drawn widespread criticism from MPs across party lines. Health Secretary Wes Streeting separately announced a £237 million investment to expand Community Diagnostic Centres across England to improve timely cancer diagnosis, stating that a diagnosis "shouldn't be a question of luck." However, this coincided with warnings from the UNISON trade union that over 20,000 NHS jobs could be at risk due to a growing £1.1 billion deficit.
Why It Matters
The controversy strikes at the heart of the NHS's founding principle — that healthcare should be allocated on the basis of clinical need, not commercial interest. If the critics' projections are even partially correct, the deal could represent one of the most consequential decisions affecting public health in a generation.
What's Next
MPs are expected to demand a parliamentary debate on the deal. The Bureau of Investigative Journalism's full investigation is available at thebureauinvestigates.com. Independent health economists are calling for a full independent review before the deal takes effect.
